| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
|
J Natl Cancer Inst
|
1992
|
1.61
|
|
2
|
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
|
Clin Pharmacol Ther
|
2010
|
1.36
|
|
3
|
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
|
Diabetes Obes Metab
|
2011
|
1.10
|
|
4
|
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
|
J Clin Oncol
|
1996
|
1.07
|
|
5
|
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
|
Diabetes Obes Metab
|
2011
|
1.03
|
|
6
|
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
|
Cancer Res
|
1994
|
1.03
|
|
7
|
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
|
Cancer Res
|
1994
|
1.01
|
|
8
|
Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid.
|
Biochem Pharmacol
|
1991
|
0.95
|
|
9
|
The spontaneous and glutathione S-transferase-mediated reaction of chlorambucil with glutathione.
|
Cancer Commun
|
1990
|
0.91
|
|
10
|
Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.
|
Diabetes Obes Metab
|
2011
|
0.89
|
|
11
|
Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients.
|
Cancer Res
|
1990
|
0.88
|
|
12
|
Phase I pharmacokinetic study of intraperitoneal etoposide.
|
Cancer Res
|
1991
|
0.84
|
|
13
|
A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.
|
Pharmacotherapy
|
2000
|
0.84
|
|
14
|
Increased levels of glutathione S-transferase pi transcript as a mechanism of resistance to ethacrynic acid.
|
Biochem J
|
1992
|
0.82
|
|
15
|
Clinical, pharmacokinetic and biological studies of topotecan.
|
Cancer Chemother Pharmacol
|
1994
|
0.79
|
|
16
|
Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.
|
Pharmacotherapy
|
2000
|
0.79
|
|
17
|
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
|
J Clin Oncol
|
1992
|
0.78
|
|
18
|
5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver.
|
Cancer Res
|
1988
|
0.78
|
|
19
|
Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.
|
Pharmacotherapy
|
2000
|
0.78
|
|
20
|
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
|
Invest New Drugs
|
1997
|
0.78
|
|
21
|
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach.
|
Cancer Chemother Pharmacol
|
1993
|
0.76
|
|
22
|
Phase I study of the mitomycin C analogue BMS-181174.
|
Br J Cancer
|
1998
|
0.75
|
|
23
|
Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.
|
Br J Cancer
|
1993
|
0.75
|
|
24
|
SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma.
|
Biochem Pharmacol
|
1993
|
0.75
|
|
25
|
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
|
J Natl Cancer Inst
|
1991
|
0.75
|
|
26
|
Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
|
Diabetes Obes Metab
|
2012
|
0.75
|
|
27
|
Chromatographic analysis of methylmercaptopurine riboside in human plasma and urine.
|
J Chromatogr
|
1991
|
0.75
|
|
28
|
High-performance liquid chromatographic analysis of fluoropyrimidine nucleosides and fluorouracil in plasma.
|
J Chromatogr
|
1987
|
0.75
|
|
29
|
High-performance liquid chromatographic analysis of N,N',N"-triethylenethiophosphoramide in human plasma.
|
J Chromatogr
|
1989
|
0.75
|
|
30
|
Pharmacology and clinical investigation of SR-2508 (etanidazole).
|
Cancer Treat Res
|
1991
|
0.75
|
|
31
|
Improved chromatographic method for the determination of trimetrexate in urine.
|
J Chromatogr
|
1990
|
0.75
|
|
32
|
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
1995
|
0.75
|
|
33
|
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
|
Cancer Chemother Pharmacol
|
1996
|
0.75
|
|
34
|
Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver.
|
Cancer Res
|
1987
|
0.75
|
|
35
|
Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
|
Pharmacotherapy
|
2000
|
0.75
|
|
36
|
High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine.
|
J Chromatogr
|
1993
|
0.75
|